Form 8-K - Current report:
SEC Accession No. 0001367644-25-000083
Filing Date
2025-03-24
Accepted
2025-03-21 17:34:07
Documents
14
Period of Report
2025-03-19
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K ebs-20250319.htm   iXBRL 8-K 29893
2 EX-99.1 pressrelease-3192025bayvie.htm EX-99.1 9636
  Complete submission text file 0001367644-25-000083.txt   166735

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ebs-20250319.xsd EX-101.SCH 1848
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ebs-20250319_lab.xml EX-101.LAB 21885
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ebs-20250319_pre.xml EX-101.PRE 12564
16 EXTRACTED XBRL INSTANCE DOCUMENT ebs-20250319_htm.xml XML 2722
Mailing Address 300 PROFESSIONAL DR GAITHERSBURG MD 20879
Business Address 300 PROFESSIONAL DR GAITHERSBURG MD 20879 240-631-3200
Emergent BioSolutions Inc. (Filer) CIK: 0001367644 (see all company filings)

EIN.: 141902018 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33137 | Film No.: 25761691
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)